The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis
| Autor: | Kriti Thapa, Matthew L Romo, Arturo Carpio, Denise Leslie, Howard Andrews, W Allen Hauser, Elizabeth A Kelvin |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Gastrointestinal Diseases Headache Disorders Administration Oral Albendazole Neurocysticercosis Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Double-Blind Method Taenia solium Animals Humans 030212 general & internal medicine Gait Disorders Neurologic Anthelmintics Muscle Weakness Public Health Environmental and Occupational Health Original Articles General Medicine Treatment Outcome Infectious Diseases Prednisone Drug Therapy Combination Female Parasitology 030217 neurology & neurosurgery |
| Zdroj: | Transactions of The Royal Society of Tropical Medicine and Hygiene. 112:73-80 |
| ISSN: | 1878-3503 0035-9203 |
| DOI: | 10.1093/trstmh/try023 |
| Popis: | There is little information about the impact of anthelminthic treatment on clinical symptoms other than seizures in neurocysticercosis (NC). We investigated the effect of albendazole on non-seizure symptoms experienced by patients with NC.Data are from a randomized controlled trial comparing albendazole plus prednisone with placebo plus prednisone for treatment of NC among 173 patients with active or transitional NC cysts and new-onset symptoms. We performed negative binomial regression to examine the number of follow-up visits when a symptom was reported, logistic regression to examine the probability of experiencing the symptom and Cox proportional hazards models to examine the time to first reporting the symptom.Eighty-five percent of patients reported at least one non-seizure symptom at baseline. Those treated with albendazole had significantly lower odds of memory loss and/or confusion during months 1-24 (odds ratio [OR] 0.42, p=0.037) and significantly increased odds of anxiety and/or depression during months 1-12 (OR 1.87, p=0.049). No treatment difference existed in experiencing symptoms in general or in experiencing headaches, limb weakness or gait disturbances, vomiting, nausea and/or stomach pain or visual disturbances over the follow-up period.While the prevalence of non-seizure symptoms was high, albendazole treatment was associated with only two significant differences in the non-seizure symptoms over follow-up. Further research is needed to identify strategies to reduce the long-term symptom burden in patients with NC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|